Evidence map›Paper›PMID 41889986›Full record

ArticlebioRxiv : the preprint server for biology2026

Anti-inflammatory and pro-proliferative effects of fasudil in human trisomy 21 neural progenitor cells.

Laura L Baxter, Sarah E Lee, Kevin A Fuentes, Iman A Mosley, Jonathan D Raymond, Faycal Guedj, Di Zhou, Donna K Slonim, Elliot J Glotfelty, David Tweedie and 2 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Laura L BaxterCenter for Precision Health Research, Prenatal Genomics and Therapy Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-7941-1088
Sarah E LeeCenter for Precision Health Research, Prenatal Genomics and Therapy Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Kevin A FuentesCenter for Precision Health Research, Prenatal Genomics and Therapy Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Iman A MosleyCenter for Precision Health Research, Prenatal Genomics and Therapy Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Jonathan D RaymondCenter for Precision Health Research, Prenatal Genomics and Therapy Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Faycal GuedjCenter for Precision Health Research, Prenatal Genomics and Therapy Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Di ZhouDepartment of Computer Science, Tufts University, Medford, MA, USA.
Donna K SlonimDepartment of Computer Science, Tufts University, Medford, MA, USA.
Elliot J GlotfeltyCellular Stress and Inflammation Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.
David TweedieDrug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Nigel H GriegDrug Design & Development Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
Diana W BianchiCenter for Precision Health Research, Prenatal Genomics and Therapy Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

Prenatal Treatment of Down Syndrome to Improve Brain Development and NeurocognitionZIAHG200399 · NHGRI · NATIONAL HUMAN GENOME RESEARCH INSTITUTE · PI BIANCHI, DIANA · 2017 to 2025
$11.1M
Design And Development Of Experimental TherapeuticsZ01AG000311 · NIA · NATIONAL INSTITUTE ON AGING · PI GREIG, NIGEL H. · 2001 to 2008
$1.7M
Intramural NIH HHS Z01 AG000311Intramural NIH HHS ZIA HG200399
6 · The paper itself

Abstract

Down syndrome (DS) results from trisomy for human chromosome 21 and is the most frequent genetic cause of intellectual disability. No effective treatments currently exist that improve neurodevelopment and cognition. Atypical brain development in individuals with DS is apparent before birth, which suggests that the optimal time to begin administration of therapies is prenatally. Human neural progenitor cell (NPC) cultures provide a tractable

Identifiers

PMID41889986
PMCPMC13015371

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.